News Lawrence Steinman honored for research on ties between EBV, MS Lawrence Steinman honored for research on ties between EBV, MS Professor of neurology is also leading development of PAS002 in MS treatment by Teresa Carvalho, MS | February 20, 2023 Share this article: Share article via email Copy article link Lawrence Steinman, MD, a professor of neurology who is leading the development of Pasithea Therapeutics‘ PAS002 for the treatment of multiple sclerosis (MS) has received the 2023 Pioneer in Medicine Award. The prize is given by the Society for Brain Mapping & Therapeutics (SBMT) and the World Brain Mapping Foundation to physicians, engineers, and researchers who have made significant contributions in the field of brain mapping and therapeutics. Steinman received the award for his contributions in identifying the similarities between the Epstein-Barr virus (EBV) protein EBNA-1 and the brain protein GlialCAM that may underlie MS development. The award was delivered last week at the 20th Annual Encounter for the Cure, part of the 20th Annual World Congress of SBMT. āIt is an honor to be recognized by such a prestigious body of peers, especially in its 20th year of leadership in the field of brain mapping and therapeutics,ā Steinman, Pasitheaās chairman and a professor at the National Academy of Sciences, said in a company press release. āMS is a debilitating disease that requires research into effective therapies and innovation in immunization. I dedicate my career to advancing these therapies for the thousands suffering from neurological diseases globally,ā added Steinman, who was involved in the development of TysabriĀ (natalizumab) and Briumvi (ublituximab), two approved MS therapies. Recommended Reading February 7, 2023 News by Marisa Wexler, MS Primary progressive MS confirmed as own disorder in mouse study EBV a leading cause of MS In MS, the immune system wrongly attacks myelin, a fatty substance that covers nerve fibers and is essential for rapid neuronal communication. EBV has recently emerged as a leadingĀ cause of MS, increasing its risk by 32 times, and Steinman and his colleagues demonstrated the association between the viral infection and the neurodegenerative condition may be attributed to resemblances between two proteins, which is known as molecular mimicry. GlialCAM is a molecule predominantly present in oligodendrocytes, the cells chiefly responsible for producing myelin in the brain and spinal cord. In their study, the researchers showed GlialCAM bears structural resemblances to an EBV protein called EBNA-1. Thus, when the body mounts an immune response against the viral protein, it also ends up attacking GlialCAM, leading to myelin loss and nerve damage. The findings prompted Pasithea to develop its PAS002, a vaccine that aims to dampen the harmful immune attacks on myelin by promoting immune tolerance to GlialCAM. The DNA vaccine delivers GlialCAM’s DNA to the body, triggering the production of the GlialCAM protein by the body’s cellular machinery. Once produced, the protein is seen as safe by the immune system because it is a part of the body’s natural components. According to data from a preclinical study, PAS002 successfully prevented the disease from developing in 50% of mice with experimental autoimmune encephalomyelitis (EAE), a common mouse model of MS. In animals that developed symptoms, the treatment also significantly decreased the severity of the disease. Now, the prize distinguished Steinman for his āpioneering work in the field, including elucidating the molecular mimicry between EBNA-1 and GlialCAM, and its role in the pathogenesis of MS,ā SBMT noted. Previous recipients of the award include Nobel Prize winner Eric Kandel, MD, and Michael E. Phelps, PhD, the inventor of positron emission tomography (PET) scans. Print This Page About the Author Teresa Carvalho, MS Teresa holds her Master of Science in cell and molecular biology from Coimbra University, Portugal. She was a researcher and science communicator for several years at the Institute for Research and Innovation in Health in Oporto, Portugal. From 2013, she has held a fellowship working with Pulmonary Hypertension Europe as a patient advocate, social media/website manager, public relations officer, and translator. Her work has been focused on providing patients access to treatments, raising awareness for pulmonary hypertension, and promoting patient empowerment. Tags Epstein-Barr virus (EBV), MS treatment
April 10, 2024 News by Margarida Maia, PhD Immune signatures may predict MS course, treatment response
January 26, 2024 News by Marisa Wexler, MS MS guidelines by Spanish society stress early, effective treatment